Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Exclusive: EU regulators seen clearing $25 billion Abbott, St Jude deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/15/2016 | 05:52pm EST
Traders gather at the booth that trades Abbott Laboratories on the floor of the New York Stock Exchange

(Reuters) - EU antitrust regulators are expected to give conditional clearance to U.S. medical device maker Abbott Laboratories' (>> Abbott Laboratories) $25 billion bid for rival St. Jude Medical Inc (>> St. Jude Medical, Inc.), a person familiar with the matter said on Tuesday.

(Reuters) - EU antitrust regulators are expected to give conditional clearance to U.S. medical device maker Abbott Laboratories' (>> Abbott Laboratories) $25 billion bid for rival St. Jude Medical Inc (>> St. Jude Medical, Inc.), a person familiar with the matter said on Tuesday.

A spokesman for the European Commission, which is due to decide on the deal by Nov. 23, declined to comment. Abbott, which also makes prescription drugs and diagnostics, had no immediate comment. St. Jude officials could not be reached for comment.

Abbott Chief Executive Miles White in October said he hoped to acquire St. Jude by the end of the year, despite lingering questions about the safety of its implantable heart devices.

The suburban Chicago company announced the St. Jude deal in April to expand its heart device business and help it compete against larger rivals Medtronic Plc (>> Medtronic PLC) and Boston Scientific Corp (>> Boston Scientific Corporation).

The companies offered concessions to address the European Commission's concerns on Oct. 31 but did not disclose details.

However, two weeks before that, they announced the sale of some of their medical devices worth about $1.12 billion to Japanese company Terumo Corp (>> Terumo Corp), saying the move was part of their deal.

The all-cash transaction included St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath.

St. Jude is facing multiple problems, including an investigation by the U.S. Food and Drug Administration over claims its heart devices have defects that make them vulnerable to fatal cyber hacks.

The company sued short-seller Muddy Waters and its investment partner, cyber research firm MedSec Holdings, after they claimed flaws in the cyber security of its devices. MedSec warned the alleged flaws could cause implanted devices to pace at potentially dangerous rates or have their batteries drained.

After Abbott reported stronger than expected earnings on Oct. 19, White praised the way St. Jude has handled Muddy Waters' allegations.

In an unrelated matter last month, St. Jude said it will recall some of its 400,000 implanted heart devices due to the risk of premature battery depletion, a condition linked to two deaths in Europe.

Shares of Abbott and St. Jude both closed 1.6 percent higher on Tuesday amid moderate gains for the broad stock market.

Mergers in the sector have underscored the pressure felt by medical equipment makers to scale up and offer a wider range of products to hospital customers.

(Reporting by Foo Yun Chee in Brussels; Additional reporting by Natalie Grover in Bengaluru and Ransdell Pierson in New York; Editing by Ruth Pitchford and Matthew Lewis)

By Foo Yun Chee

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -1.88% 83.87 Delayed Quote.15.95%
BOSTON SCIENTIFIC CORPORATION -0.84% 43.71 Delayed Quote.23.68%
MEDTRONIC PLC -1.73% 111.13 Delayed Quote.22.17%
TERUMO CORPORATION -1.61% 3787 End-of-day quote.-37.67%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
11/19ABBOTT LABORATORIES : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/14Abbott's White To Step Down as Chief Executive -- WSJ
DJ
11/13Longtime Abbott Labs CEO Miles White to Step Down in March -- 2nd Update
DJ
11/13Longtime Abbott Labs CEO Miles White to Step Down in March -- Update
DJ
11/13ABBOTT LABORATORIES : Change in Directors or Principal Officers, Amendments to A..
AQ
11/13ABBOTT LABORATORIES : Labs veteran CEO White to step down next March
AQ
11/13ROBERT FORD : Abbott Labs Names Ford to Succeed White as CEO in March
DJ
11/13ABBOTT : Announces Robert B. Ford to Succeed Miles D. White as Chief Executive O..
PR
11/12ABBOTT LABORATORIES : Other Events (form 8-K)
AQ
11/11Corporate Briefing Session of Abbott Laboratories Limited
AQ
More news
Financials (USD)
Sales 2019 31 851 M
EBIT 2019 7 153 M
Net income 2019 3 655 M
Debt 2019 13 029 M
Yield 2019 1,51%
P/E ratio 2019 40,0x
P/E ratio 2020 33,2x
EV / Sales2019 5,07x
EV / Sales2020 4,54x
Capitalization 148 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 93,29  $
Last Close Price 83,87  $
Spread / Highest target 31,2%
Spread / Average Target 11,2%
Spread / Lowest Target -16,5%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President & Chief Operating Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES15.95%148 320
MASIMO CORPORATION41.76%8 117
NOVOCURE LIMITED142.86%8 047
ASAHI INTECC CO., LTD.-31.71%7 383
PENUMBRA, INC.31.86%5 626
GETINGE116.40%4 911